Aclaris Therapeutics (NASDAQ: ACRS) revenue
Aclaris Therapeutics reported revenue of $7.8m for fiscal 2025, 58.2% less than in fiscal 2024 ($18.7m). Since fiscal 2017 its revenue has grown by 365.0%, an average growth of 21.2% a year.
Aclaris Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 9 was fiscal 2023. The biggest drop was in fiscal 2025, −58.2%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $7.8m | −58.2% | −$76.4m | −975.9% |
| 2024 | $18.7m | −40.1% | −$141.9m | −758.2% |
| 2023 | $31.2m | +5.0% | −$97.4m | −311.6% |
| 2022 | $29.8m | +340.1% | −$89.9m | −302.0% |
| 2021 | $6.8m | +4.3% | −$89.7m | −1,327.1% |
| 2020 | $6.5m | +53.3% | −$50.9m | −785.4% |
| 2019 | $4.2m | −31.3% | −$111.1m | −2,627.3% |
| 2018 | $6.2m | +265.5% | −$84.8m | −1,378.3% |
| 2017 | $1.7m | — | −$54.4m | −3,230.0% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Aclaris Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Aclaris Therapeutics ranks 374th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Aclaris Therapeutics, −58.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 372nd | Bioage Labs | $9.0m | — |
| 373rd | Roivant Sciences | $8.3m | −71.6% |
| 374th | Aclaris Therapeutics | $7.8m | −58.2% |
| 375th | Xenon Pharmaceuticals | $7.5m | — |
| 376th | Ovid Therapeutics | $7.3m | 1,181.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Aclaris Therapeutics
- How much revenue did Aclaris Therapeutics make in fiscal 2025?
- Aclaris Therapeutics reported revenue of $7.8m for fiscal 2025, compared with $18.7m in fiscal 2024.
- How much has the revenue of Aclaris Therapeutics grown?
- Between fiscal 2017 and fiscal 2025 it went from $1.7m to $7.8m: 365.0% more, an average growth of 21.2% a year.
- What was the best year for revenue at Aclaris Therapeutics?
- Of its last 9 fiscal years, fiscal 2023, with $31.2m.
- Where does Aclaris Therapeutics rank in its sector by revenue?
- It ranks 374th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Aclaris Therapeutics come from?
- From the annual report (Form 10-K) that Aclaris Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Aclaris Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Aclaris Therapeutics: the Aclaris Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.